Taylor Wimpey (OTCMKTS:TWODY – Free Report) and Zealand Pharma A/S (OTCMKTS:ZLDPF – Free Report) are both mid-sized construction companies, but which stock is better? We will compare the two companies based on their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Volatility and risk
Taylor Wimpey has a beta of 1.82, meaning its share price is 82% more volatile than the S&P 500. For comparison, Zealand Pharma A/S has a beta of 0.89, meaning its share price is 11% less volatile than the S&P 500.
Valuation & Income
This table compares revenue, earnings per share (EPS) and valuation of Taylor Wimpey and Zealand Pharma A/S.
| Gross revenue | Price/sales ratio | Net income | Earnings per share | Price-earnings ratio | |
| Taylor Wimpey | 4.37 billion US dollars | 1.47 | 433.99 million US dollars | N/A | N/A |
| Zealand Pharma A/S | 49.75 million US dollars | 115.50 | -102.18 million US dollars | (1.82 USD) | -61.29 |
Taylor Wimpey has higher sales and profits than Zealand Pharma A/S.
Analyst ratings
This is a summary of the latest ratings and recommendations for Taylor Wimpey and Zealand Pharma A/S, as reported by MarketBeat.
| Sales ratings | Keep ratings | Buy reviews | Strong buy recommendations | Evaluation result | |
| Taylor Wimpey | 0 | 0 | 0 | 0 | N/A |
| Zealand Pharma A/S | 0 | 0 | 2 | 0 | 3.00 |
profitability
This table compares the net margins, return on equity and return on assets of Taylor Wimpey and Zealand Pharma A/S.
| Net margins | Return on equity | Return on total assets | |
| Taylor Wimpey | N/A | N/A | N/A |
| Zealand Pharma A/S | -213.77% | -36.96% | -30.10% |
Summary
Taylor Wimpey beats Zealand Pharma A/S on 6 of the 8 factors compared between the two stocks.
About Taylor Wimpey
(Get free report)
Taylor Wimpey plc operates as a housebuilder in the United Kingdom and Spain. The company builds and supplies a variety of houses and residential developments. Taylor Wimpey plc was founded in 1935 and is based in High Wycombe, United Kingdom.
About Zealand Pharma A/S
(Get free report)
Zealand Pharma A/S, a biotechnology company, is engaged in the discovery, development and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focused on gastrointestinal and metabolic diseases and other specialty disease areas with unmet medical needs. The company offers dasiglucagon, a single-use syringe or auto-injector for the treatment of severe hypoglycemia, and dasiglucagon bihormone systems for artificial pancreases containing insulin and dasiglucagon. Its product pipeline includes dasiglucagon, which is in Phase III clinical trials for the treatment of congenital hyperinsulinism. The company is also developing glepaglutide, a long-acting GLP-2 analogue, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was founded in 1997 and is based in Søborg, Denmark.
Get daily news and reviews about Taylor Wimpey – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Taylor Wimpey and related companies with MarketBeat.com’s FREE daily email newsletter.
